Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8616416 | 0.83 | CTNNB1 (0.56) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL20508992 | 0.82 | PTPN1 (0.74) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL30089515 | 0.82 | CTNNB1 (0.68) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL9111787 | 0.80 | CTNNB1 (0.53) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL14732971 | 0.80 | CTNNB1 (0.61) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL8343202 | 0.80 | CES2 (0.60) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL30842876 | 0.80 | CES2 (0.60) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL167448 | 0.80 | CES2 (0.60) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL28620969 | 0.79 | CTNNB1 (0.51) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL8396548 | 0.78 | PTPN1 (0.58) | PTPN1ERCC5FEN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1301264-A | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists | ABBOTT LAB (US) | 2001-06-27 | — | — | CN | disclosed |
| EP-0035820-B1 | NOVEL QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHOD FOR THE PREPARATION OF THESE COMPOUNDS | ACF CHEMIEFARMA NV (NL) | 1984-10-10 | — | — | EP | disclosed |
| US-4472403-A | Quinoline derivatives and pharmaceutical compositions and methods for treating cardiovascular disease with such compounds | A.C.F. CHEMIEFARMA N.V. (NL) | 1984-09-18 | — | — | US | disclosed |
| US-4442106-A | HYPOTENSIVE, ANTIARRHYTHMIA | ACF CHEMIEFARMA N.V. (NL) | 1984-04-10 | — | — | US | disclosed |
| EP-0035820-A2 | Novel quinoline derivatives, pharmaceutical compositions containing such compounds, and method for the preparation of these compounds | ACF CHEMIEFARMA NV (NL) | 1981-09-16 | — | — | EP | disclosed |
| EP-0030044-A1 | Quinoline derivatives, processes for their preparation, their use, pharmaceutical compositions containing them and a method for the preparation of these pharmaceutical compositions | ACF CHEMIEFARMA NV (NL) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PTPN1 1427/4885ERCC5 4470/4885FEN1 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.